References
- Akiba T, Miyazaki M, Toda N. Vasodilator actions of TRK-100 a new prostaglandin I2 analogue. Br J Pharmacol 1986; 89: 703–711
- Belch J JF, McKay A, McArdle B, et al. Epoprostenol (prostacyclin) and severe arterial disease: a double blind trial. Lancet 1983; 1: 315–317
- Cho M J, Allen M A. Chemical stability of prostacyclin (PGI2) in aqueous solutions. Prostaglandins 1978; 15: 943–954
- Crabb D J, Niall M, Knight K, Angus J, O'Brien B. Topical use of prostacyclin in microvascular surgery. Br J Plast Surg 1985; 38: 383–388
- El Tahir K EH, Williams K I, Betteridge D J. Differences in the stability of prostacyclin in human, rabbit and rat plasma. Prostaglandins Leukot Med 1983; 10: 109–114
- Emerson D JM, Sykes P J. The effect of prostacyclin on experimental random pattern flaps in the rat. Br J Plast Surg 1981; 34: 264–266
- Galla T, Saetzler R KE, Hammersen F, Messmer K. Increase in skin flap survival by the vasoactive drag Buflomedil. Plast Reconstr Surg 1991; 87: 130–136
- Hammond D, Brooksher R, Mann R, Beernink J. The dorsal skin flap model in the rat: Factors influencing survival. Plast Reconstr Surg 1993; 91: 316–321
- Higgs G A, Higgs E A, Salmon J A. Prostacyclin in inflammation. Prostacyclin, J R Vane, S Bergstrom. Raven Press, New York 1979; 187–193
- Knight K, Crabb D J, Niall M, et al. Pharmacologic modification of blood flow in the rabbit with prostacyclin and related drugs. Plast Reconstr Surg 1985; 75: 692–700
- Moncada S, Gryglewski R, Bunting S, Vane J R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663–665
- Murata T, Murai T, Kanai T, et al. General Pharmacology of Beraprost Sodium. 2nd communication: Effect on the autonomic, cardiovascular and gastrointestinal systems and other effects. Arzneimittelforschung Drug Res 1989; 39: 867–876
- Nickolson R C, Town M H, Vorbruggen H. Prostacyclin-analogs. Med Res Rev 1985; 5: 1–53
- Nishio S, Matsuura H, Kanai N, et al. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog in several species. Jpn J Pharmacol 1988; 47: 1–10
- Nishio S, Yamada N., Endoh T, et al. Effect of Beraprost Sodium on peripheral circulatory disturbances induced by various stimuli. Arzneimittelforschung Drug Res 1989; 39: 1229–1234
- Ohno K, Nagase H, Matsumoto K, Nishivama H, Nishio S. Stereoselective synthesis of 5,6,7-trinor-4,8-inter-m-phenylene-PG12 derivatives and their inhibitory activities to human platelet aggregation. Adv Prostaglandin Thromboxane Leukot Res 1985; 15: 279–281
- Sasaki G, Pang C Y. Experimental evidence for involvement of prostaglandins in viability of actue flaps: Effects on viability and mode of action. Plast Reconstr Surg 1981; 67: 335–340
- Sim A K, McCraw A P, Cleland M E, Nishio S, Umetsu T. The effect of a stable prostacyclin analogue on platelet function and experimentally induced thrombosis in the microcirculation. Arzneimittelforschung Drug Res 1985; 35: 1816–1818
- Simpson P J, Mitsos S E, Ventura A, et al. Prostacyclin protects ischemic reperfused myocardium in the dog by inhibition of neutrophil activation. Am Heart J 1987; 113: 129–137
- Sinzinger H, Silberbauer K, Horsch A K, Gall A. Decreased sensitivity of human platelets to PG12 during long term intraarterial prostacyclin infusion in patients with peripheral vascular disease A rebound phenomenon. Prostaglandins 1981; 21: 49–51
- Smith R J, Birndorf M, Duck B SG, et al. The effect of low energy laser on skin flap survival in the rat and porcine models. Plast Reconstr Surg 1992; 89: 306–310
- Sturzebecher S., Harberey Mullar M. B, et al. Pharmacological profile of a novel carbacyclin derivative with high metabolic stability and oral activity in the rat. Prostaglandins 1986; 31: 95–109
- Umetsu T, Murata T, Tanaka Y, Osada E, Nishio S. Antithrombotic effect of TRK-100, a novel, stable PG12 analogue. Jpn J Pharmacol 1987; 43: 81–90
- Umetsu T, Murata T, Nishio S. Studies on the antiplatelet effect of the stable epoprostenol analogue beraprost sodium and its mechanism of action in rats. Arzneimittelforschung Drug Res 1989; 39: 68–73
- Vedder N B, Bucky L P, Richey N, et al. Improved survival rates of random flaps in rabbits with a monoclonal antibody that blocks leukocyte adherence. Plast Reconstr Surg 1994; 93: 1035–1040
- Zachary L S, Heggens J P, Robson M C, Murphy R C. Combined prostacyclin and thromboxane synthetase inhibitor UK-38 485 in flap survival. Ann Plast Surg 1986; 17: 112–115